BR112014017814A8 - Anticorpos anti-cxcr3 - Google Patents

Anticorpos anti-cxcr3

Info

Publication number
BR112014017814A8
BR112014017814A8 BR112014017814A BR112014017814A BR112014017814A8 BR 112014017814 A8 BR112014017814 A8 BR 112014017814A8 BR 112014017814 A BR112014017814 A BR 112014017814A BR 112014017814 A BR112014017814 A BR 112014017814A BR 112014017814 A8 BR112014017814 A8 BR 112014017814A8
Authority
BR
Brazil
Prior art keywords
cxcr3
antibodies
binding
cxcr3 antibodies
diagnose
Prior art date
Application number
BR112014017814A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014017814A2 (https=
Inventor
Youd Michele
Tedstone Jennifer
Lodie Tracey
B Carter Karen
D Connors Timothy
Robert Pinckney Jason
Masterjohn Elizabeth
Chu Ruiyin
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112014017814A2 publication Critical patent/BR112014017814A2/pt
Publication of BR112014017814A8 publication Critical patent/BR112014017814A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112014017814A 2012-01-20 2013-01-18 Anticorpos anti-cxcr3 BR112014017814A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261588936P 2012-01-20 2012-01-20
PCT/US2013/022280 WO2013109974A2 (en) 2012-01-20 2013-01-18 Anti-cxcr3 antibodies

Publications (2)

Publication Number Publication Date
BR112014017814A2 BR112014017814A2 (https=) 2017-06-20
BR112014017814A8 true BR112014017814A8 (pt) 2017-07-11

Family

ID=47633576

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014017814A BR112014017814A8 (pt) 2012-01-20 2013-01-18 Anticorpos anti-cxcr3

Country Status (26)

Country Link
US (4) US8865870B2 (https=)
EP (1) EP2804878B1 (https=)
JP (3) JP6352812B6 (https=)
KR (2) KR20200014441A (https=)
CN (1) CN104507967B (https=)
AR (1) AR090056A1 (https=)
AU (1) AU2013209492B2 (https=)
BR (1) BR112014017814A8 (https=)
CA (1) CA2862222A1 (https=)
CY (1) CY1121335T1 (https=)
DK (1) DK2804878T3 (https=)
ES (1) ES2698606T3 (https=)
HR (1) HRP20181874T1 (https=)
HU (1) HUE041900T2 (https=)
IL (2) IL233694A0 (https=)
LT (1) LT2804878T (https=)
MX (1) MX359854B (https=)
PL (1) PL2804878T3 (https=)
PT (1) PT2804878T (https=)
RS (1) RS58141B1 (https=)
RU (1) RU2663141C2 (https=)
SG (2) SG11201406762QA (https=)
SI (1) SI2804878T1 (https=)
TW (1) TWI596112B (https=)
UY (1) UY34582A (https=)
WO (1) WO2013109974A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EA201790437A1 (ru) 2014-08-22 2017-08-31 Сорренто Терапьютикс, Инк. Антигенсвязывающие белки, связывающиеся с cxcr3
CA3003458A1 (en) 2015-10-29 2017-05-04 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
EP3464349A4 (en) * 2016-05-23 2020-08-26 New York University COMPOSITIONS AND METHODS ASSOCIATED WITH ANTIBODIES TARGETING STAPHYLOCCAL LEUCOTOXINS
TW201837053A (zh) * 2016-12-22 2018-10-16 法商賽諾菲公司 具有消耗活性的人源化cxcr3抗體及其使用方法
EP3559036A1 (en) * 2016-12-22 2019-10-30 Sanofi Anti-human cxcr3 antibodies for treatment of vitiligo
US20180244787A1 (en) 2016-12-22 2018-08-30 Sanofi Anti-human cxcr3 antibodies for treatment of vitiligo
JP7384811B2 (ja) * 2018-02-16 2023-11-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 白斑を処置するための方法及び組成物
KR102074798B1 (ko) * 2018-06-15 2020-02-07 코아스템(주) 자가면역질환 치료에 대한 유효성 예측용 바이오마커, 진단키트 및 치료용 용도
JP2022507295A (ja) * 2018-11-14 2022-01-18 アーチ オンコロジー，インコーポレイテッド 治療用ＳＩＲＰα抗体
BR112022017048A2 (pt) 2020-02-26 2022-11-16 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos para usar os mesmos
BR112022021992A2 (pt) * 2020-04-30 2023-01-03 Arch Oncology Inc Método de tratamento de câncer em um sujeito em necessidade do mesmo
EP4288455A1 (en) 2021-02-03 2023-12-13 Mozart Therapeutics, Inc. Binding agents and methods of using the same
US20250277026A1 (en) * 2021-03-02 2025-09-04 Novarock Biotherapeutics, Ltd. Antibodies against claudin-6 and uses thereof
CN118103070A (zh) * 2021-08-09 2024-05-28 默克专利有限公司 解偶联t细胞介导的肿瘤细胞毒性与促炎细胞因子释放的蛋白质
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
US20250381184A1 (en) 2022-09-09 2025-12-18 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising an anti-cd3 antibody and a cxcr3 antagonist
WO2025185738A1 (zh) * 2024-03-08 2025-09-12 演生潮(北京)生物科技有限公司 靶向cxcr3的抗原结合蛋白及其应用
WO2026069312A1 (en) 2024-09-24 2026-04-02 Yeda Research And Development Co. Ltd. Immune cells expressing an inducible therapeutic agent and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565332A (en) 1896-08-04 Toy for making soap-bubbles
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE229046T1 (de) 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
JP2826272B2 (ja) 1993-10-26 1998-11-18 タイガースポリマー株式会社 中空樹脂成形品の製造装置及び製造方法
US5565352A (en) 1993-11-24 1996-10-15 Arch Development Corporation Deubiquitinating enzyme: compositions and methods
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
AU734090B2 (en) * 1996-09-10 2001-06-07 Millennium Pharmaceuticals, Inc. CXCR3 chemokine receptor, antibodies, nucleic acids, and methods of use
US6140064A (en) * 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2001249546A1 (en) * 2000-03-27 2001-10-08 Corixa Corporation Methods for treating disease with antibodies to cxcr3
WO2003029471A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
BRPI0411945A (pt) * 2003-06-30 2006-10-24 Bio Technology General Israel Anticorpos e seus usos
WO2005030793A2 (en) 2003-09-24 2005-04-07 Millennium Pharmaceuticals, Inc. Antibodies which bind human cxcr3
ATE557042T1 (de) * 2004-03-23 2012-05-15 Lilly Co Eli Anti-myostatin-antikörper
AU2005334481A1 (en) 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
AU2007238034A1 (en) 2006-04-14 2007-10-25 Trubion Pharmaceuticals Inc. Binding proteins comprising immunoglobulin hinge and Fc regions having altered Fc effector functions
JP5371780B2 (ja) * 2007-02-01 2013-12-18 テバ バイオファーマシューティカルズ ユーエスエー インコーポレーティッド Ｃｘｃｒ３に対するヒト化抗体
MX338397B (es) 2007-08-29 2016-04-15 Sanofi Aventis Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
WO2010056907A2 (en) 2008-11-12 2010-05-20 The Scripps Research Institute Compounds that induce pancreatic beta-cell expansion
WO2010103517A1 (en) * 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases
JP5894939B2 (ja) * 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用

Also Published As

Publication number Publication date
CY1121335T1 (el) 2020-05-29
AU2013209492A1 (en) 2014-08-14
US20130251733A1 (en) 2013-09-26
IL271697A (en) 2020-02-27
JP2015506945A (ja) 2015-03-05
US20190119391A1 (en) 2019-04-25
US9765144B2 (en) 2017-09-19
PL2804878T3 (pl) 2019-03-29
HRP20181874T1 (hr) 2019-01-11
KR20200014441A (ko) 2020-02-10
RU2014134043A (ru) 2016-03-20
JP6352812B6 (ja) 2018-08-08
DK2804878T3 (en) 2018-12-17
MX359854B (es) 2018-10-12
EP2804878B1 (en) 2018-08-22
HUE041900T2 (hu) 2019-06-28
TW201335188A (zh) 2013-09-01
MX2014008728A (es) 2015-07-06
EP2804878A2 (en) 2014-11-26
US20180086838A1 (en) 2018-03-29
PT2804878T (pt) 2018-11-29
SG11201406762QA (en) 2014-11-27
JP2020072715A (ja) 2020-05-14
CN104507967A (zh) 2015-04-08
US8865870B2 (en) 2014-10-21
SI2804878T1 (sl) 2018-12-31
US20140377806A1 (en) 2014-12-25
JP6646100B2 (ja) 2020-02-14
IL233694A0 (en) 2014-09-30
UY34582A (es) 2013-09-02
HK1208684A1 (en) 2016-03-11
CN104507967B (zh) 2018-10-12
WO2013109974A3 (en) 2013-11-07
RS58141B1 (sr) 2019-02-28
ES2698606T3 (es) 2019-02-05
JP6352812B2 (ja) 2018-07-04
TWI596112B (zh) 2017-08-21
AU2013209492B2 (en) 2018-02-08
JP2018166506A (ja) 2018-11-01
CA2862222A1 (en) 2013-07-25
KR102073034B1 (ko) 2020-02-05
WO2013109974A2 (en) 2013-07-25
AR090056A1 (es) 2014-10-15
RU2663141C2 (ru) 2018-08-01
LT2804878T (lt) 2018-12-10
KR20140116525A (ko) 2014-10-02
SG10201700735PA (en) 2017-02-27
BR112014017814A2 (https=) 2017-06-20

Similar Documents

Publication Publication Date Title
BR112014017814A8 (pt) Anticorpos anti-cxcr3
BR112012004823A8 (pt) Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
PH12021550083A1 (en) Human anti-tau antibodies
BRPI0807710A8 (pt) Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
BR112015019603A2 (pt) Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna
BR112021023048A2 (pt) Moléculas de ligação a cd19 e usos das mesmas
BR112012024710A8 (pt) moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo
BR112017027498A2 (pt) anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença.
BR112012009854B8 (pt) proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
BR112013026828A2 (pt) polipeptídeos de anticorpo que antagonizam cd40
BR112012021327B8 (pt) anticorpo monoclonal anti-her2 humanizado, método de preparação e uso do mesmo.
BR112014008775A8 (pt) Métodos para produzir camundongos com locus restrito de cadeia pesada de imunoglobulina, para obter célula ou tecido de camundongos, para produzir sequência de ácido nucleico que codifica domínio variável de cadeia pesada humano, bem como ácido nucleico
BRPI0909040A8 (pt) Derivados de azetidina e ciclobutano, seus usos, e composição
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
BR112014029099A2 (pt) anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende
BR112014006822A2 (pt) proteínas de ligação ao antígeno cd27l
BR112015023418A2 (pt) conjugado de anticorpo e fármaco, anticorpo ou fragmento de ligação de antígeno, seus processos de produção, seus usos, ácido nucleico, vetor, e célula hospedeira
BR112015008347A2 (pt) molécula de anticorpo isolada, uso de dita molécula de anticorpo, composição, ácido nucleico isolado, célula hospedeira, métodos para produção de uma molécula de anticorpo, para produzir um domínio de ligação de antígeno ao anticorpo para a?1-42 humano e para produzir um membro de ligação que se liga a a?1-42 humana.
BRPI0713000A8 (pt) Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples
BR112014011331A2 (pt) anticorpos específicos para trop-2 e seus usos
BR112014023415A2 (pt) moléculas que se ligam a ang2
BR112016024575A2 (pt) anticorpo para igf-1r e seu uso como veículo de endereçamento para o tratamento de câncer
BR112012007821A2 (pt) polipeptídeos para ligação ao "receptor de produtos finais de glicação avançada" bem como composições e métodos envolvendo os mesmos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements